While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...

Commonly used fecal immunochemical tests vary in their performance, which has implications for the benefits and ...

Developments in artificial intelligence (AI) are moving rapidly. Within gastroenterology, great interest and high expectations exist for computer-aided diagnosis (CADx) systems. These CADx systems ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

A Taipei Medical University research team found that the hemoglobin concentration levels resulting from fecal occult blood ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Researchers have discovered a new fish in Saudi Arabia that looks to be a little crabby. The Grumpy dwarfgoby, known by ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

For example, families with Lynch syndrome (LS) are at high risk of developing colorectal cancer (CRC), where the number of polyps and the frequency of colonoscopy screening visits are highly ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...